Assoc. Prof. Dr. Guoguo Jin | Medicine and Dentistry | Best Researcher Award
Deputy Director from Key Laboratory of Chronic Disease Health Management of Henan Province, China
Dr. Guoguo Jin is an accomplished biomedical researcher specializing in the chemical prevention of tumors. With a strong foundation in pathology and bioengineering, she has steadily developed a research career that bridges cancer biology and cardiovascular complications arising from oncological treatments. Her work delves into the molecular mechanisms underlying tumorigenesis, cardiotoxicity from chemotherapeutic agents, and the identification of therapeutic targets for various cancers, particularly esophageal, gastric, and colon carcinomas. Dr. Jin currently serves as the Deputy Director of both the Key Laboratory of Chronic Disease Health Management and the Department of Scientific Research and Discipline Construction at Fuwai Central China Cardiovascular Hospital. She has led several national and provincial-level research projects and has published extensively in top-tier journals. Her research contributions are complemented by multiple patents aimed at mitigating drug-induced cardiotoxicity. Recognized for her leadership and scientific acumen, she has received accolades such as the Young and Middle-aged Academic Leader title from the Health Commission of Henan Province. Overall, Dr. Jin’s work represents a compelling blend of scientific rigor, clinical relevance, and translational potential. Her continued efforts are likely to yield significant advancements in cancer therapy and patient care.
Professional Profile
Education
Dr. Guoguo Jin began her academic journey in bioengineering, earning her Master’s degree from the School of Bioengineering at Zhengzhou University in July 2011. This foundational training equipped her with critical insights into biomedical sciences and experimental techniques. She then pursued her doctoral studies in pathology and pathophysiology at the Basic Medical College of Zhengzhou University, receiving her Ph.D. in July 2017. During her doctoral program, she was selected for an international joint training opportunity and spent two years (2015–2017) at the prestigious Hormel Institute, University of Minnesota. There, she conducted in-depth research into the signal transduction pathways related to tumorigenesis and its prevention. Her time abroad not only enriched her technical competencies but also exposed her to cutting-edge methodologies in cancer biology. This combination of local and international academic training has laid a solid foundation for her ongoing research into tumor mechanisms and therapeutic strategies. Dr. Jin’s educational background reflects a trajectory of consistent academic excellence and scientific curiosity, establishing her as a capable and knowledgeable researcher in the fields of oncology and pathology.
Professional Experience
Dr. Guoguo Jin currently holds dual leadership roles at Fuwai Central China Cardiovascular Hospital, where she serves as Deputy Director of both the Key Laboratory of Chronic Disease Health Management of Henan Province and the Department of Scientific Research and Discipline Construction. Her professional responsibilities primarily involve overseeing tumor-related research and institutional academic development. Earlier in her career, she gained international experience at the Hormel Institute, University of Minnesota, where she focused on cancer signal transduction pathways. This exposure to high-impact research environments significantly influenced her approach to scientific inquiry. Throughout her career, Dr. Jin has successfully led multiple research projects funded at both national and provincial levels. These projects explore the molecular mechanisms of drug-induced cardiotoxicity, tumor progression, and the discovery of small-molecule inhibitors. Her clinical and translational research activities are closely integrated with her hospital’s goals, enhancing the relevance and impact of her findings. With a strong blend of laboratory management, project leadership, and interdepartmental coordination, Dr. Jin’s professional journey reflects her growth from a bench scientist to an influential figure in medical research administration. Her dual roles in scientific research and academic governance enable her to contribute meaningfully to both science and institutional progress.
Research Interest
Dr. Guoguo Jin’s primary research interest lies in the chemical prevention of tumors, with a focus on uncovering the molecular mechanisms that drive carcinogenesis and treatment-related complications. She is particularly interested in the pathways that regulate tumor initiation and progression in gastrointestinal cancers such as esophageal, gastric, and colon cancer. A significant portion of her work also explores the cardiotoxic effects of chemotherapeutic agents like osimertinib and doxorubicin, aiming to develop strategies to mitigate these adverse outcomes. Her recent studies have investigated the roles of signaling molecules such as WNK1, hnRNPU, AHCY-LDHA, and ZIP8 in cancer development and progression. Dr. Jin is also deeply involved in the identification and evaluation of small-molecule inhibitors and natural compounds like α-mangostin and curcumin for their anti-tumor efficacy. Her research bridges basic science and clinical application, positioning her work at the forefront of translational oncology. Through the development of targeted therapies and predictive biomarkers, she aims to improve both treatment outcomes and quality of life for cancer patients. This integrated focus on cancer biology and cardiotoxicity underlines her commitment to advancing personalized medicine in oncology.
Research Skills
Dr. Guoguo Jin possesses a wide array of research skills, especially in molecular and cellular biology techniques relevant to oncology. She is proficient in signal transduction analysis, gene expression profiling, histone modification studies, and functional validation of oncogenes and tumor suppressors. Her expertise extends to the use of in vitro and in vivo cancer models to study the efficacy and mechanisms of chemopreventive agents. She has demonstrated a high level of competence in utilizing molecular techniques such as Western blotting, qRT-PCR, immunohistochemistry, and chromatin immunoprecipitation assays. Her postdoctoral training at the Hormel Institute allowed her to master advanced techniques for dissecting signaling pathways in cancer. In addition to experimental skills, Dr. Jin has a solid foundation in project design, grant writing, and data analysis. She is also skilled in translating laboratory findings into potential therapeutic applications, as demonstrated by her patents. Moreover, her ability to manage multidisciplinary teams and coordinate with clinical departments enhances the practical relevance of her research. These competencies enable her to effectively lead complex biomedical projects from conceptualization to execution and dissemination.
Awards and Honors
Dr. Guoguo Jin has received multiple awards and honors that underscore her impact and promise in the field of medical research. In February 2024, she was selected as a Young and Middle-aged Academic Leader in Health and Wellness by the Health Commission of Henan Province, a recognition of her leadership in translational cancer research. Later that year, she was awarded a position in the National-Level Talent Cultivation Project for First-Class Discipline in Clinical Medicine at Zhengzhou University. Dr. Jin has also secured several competitive research grants, including the National Natural Science Foundation Youth Project, the Science and Technology Tackling Project by the Department of Science and Technology of Henan Province, and the Outstanding Young Talent Training Program for Health and Technology Innovation. Her innovative research on cancer prevention and cardiotoxicity has led to two patents, further highlighting her commitment to developing clinically relevant solutions. These accolades reflect not only her scientific excellence but also her dedication to advancing health outcomes through rigorous and applied research. The consistent support from national and provincial agencies illustrates her status as a leading figure in her domain.
Conclusion
Dr. Guoguo Jin exemplifies the qualities of a leading researcher with her focused expertise in chemical tumor prevention and translational oncology. Her well-rounded background—from robust academic training to leadership in high-impact research—positions her as a valuable contributor to both the scientific community and clinical practice. Her studies on molecular mechanisms of cancer progression and cardiotoxicity have not only expanded academic understanding but have also offered practical pathways for improving patient outcomes. Through national and provincial grants, influential publications, and patented innovations, she continues to push the boundaries of cancer therapy and prevention. While her research is already making a meaningful impact, future expansion into international collaborations and clinical trials could further elevate her contributions. Overall, Dr. Jin’s career is marked by scientific rigor, visionary leadership, and a commitment to translating research into real-world solutions. She is a highly deserving candidate for recognition through honors such as the Best Researcher Award and is likely to make even greater strides in cancer research in the years to come.
Publications Top Notes
-
Title: STIP1 drives metabolic reprogramming in esophageal squamous cell carcinoma via AHCY-LDHA axis
Authors: Jin G, Song Y, Yan M, Fang S, Shao Y, Zhao K, Liu M, Guo Q, Jia X, Zhang C, Wang Z, Liu K, Li X, Zhao S, Guo Z, Dong Z
Year: 2025 -
Title: hnRNPU-mediated pathogenic alternative splicing drives gastric cancer progression
Authors: Jin G, Song Y, Fang S, Yan M, Yang Z, Shao Y, Zhao K, Liu M, Wang Z, Guo Z, Dong Z
Year: 2025 -
Title: ZIP8 modulates ferroptosis to drive esophageal carcinoma progression
Authors: Yang Z, Zhao K, Li X, Yanzhang R, Zhang H, Yu Y, Yan M, Fang S, Li T, Li H, Chu X, Han S, Zhang Z, Teng J, Jin G, Guo Z
Year: 2025 -
Title: Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer
Authors: Jin G, Yan M, Liu K, Yao K, Chen H, Zhang C, Yi Y, Reddy K, Gorja DR, Laster KV, Guo Z, Dong Z
Year: 2020 -
Title: Ginger extract inhibits c-MET activation and suppresses osteosarcoma in vitro and in vivo
Authors: Yanzhang R, Yan M, Yang Z, Zhang H, Yu Y, Li X, Shen R, Chu X, Han S, Zhang Z, Teng J, Li H, Li T, Jin G, Guo Z
Year: 2025 -
Title: PDK1-mediated phosphorylation of USP5 modulates NF-κB signalling to enhance osteosarcoma growth
Authors: Yang Z, Yu Z, Teng J, Yanzhang R, Yu Y, Zhang H, Jin G, Wang F
Year: 2025 -
Title: Precision therapy for cancer prevention by targeting carcinogenesis
Authors: Jin G, Liu K, Guo Z, Dong Z*
Year: 2024 -
Title: Decrypting the Molecular Mechanistic Pathways Delineating the Chemotherapeutic Potential of Ruthenium-Phloretin Complex in Colon Carcinoma Correlated with the Oxidative Status and Increased Apoptotic Events
Authors: Jin G, Zhao Z, Chakraborty T, et al.
Year: 2020 -
Title: Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma
Authors: Zhao Z, Jin G, Yao K, Liu K, Liu F, Chen H, Wang K, Gorja DR, Reddy K, Bode A.M., Guo Z, Dong Z
Year: 2019 -
Title: Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway
Authors: Li D, Wang G, Jin G, Yao K, Zhao Z, Bie L, Guo Y, Li N, Deng W, Chen X, Chen B, Liu Y, Luo S, Guo Z
Year: 2019